SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
-10.97%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$405M
AUM Growth
+$405M
(-25%)
Cap. Flow
-$58.7M
Cap. Flow
% of AUM
-14.49%
Top 10 Holdings %
Top 10 Hldgs %
35.11%
Holding
122
New
18
Increased
18
Reduced
51
Closed
9
Top Buys
| 1 |
Mineralys Therapeutics
MLYS
|
$4.36M |
| 2 |
Nova
NVMI
|
$4.16M |
| 3 |
MAZE
Maze Therapeutics, Inc. Common Stock
MAZE
|
$3.91M |
| 4 |
Sarepta Therapeutics
SRPT
|
$3.77M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
$3.47M |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$18.6M |
| 2 |
Microsoft
MSFT
|
$6.66M |
| 3 |
Meta Platforms (Facebook)
META
|
$6.36M |
| 4 |
Check Point Software Technologies
CHKP
|
$6.22M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$5.29M |
Sector Composition
| 1 | Healthcare | 78.9% |
| 2 | Technology | 13.54% |
| 3 | Consumer Discretionary | 2.19% |
| 4 | Communication Services | 2.14% |
| 5 | Utilities | 1.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Teva Pharmaceuticals
TEVA
$21.1B
| $24.2M | 5.56% | 1,572,181 +3,000 | +0.2% | +$46.1K |
|
|
2
Syndax Pharmaceuticals
SNDX
$1.41B
| $20.4M | 4.71% | 1,663,974 +282,733 | +20% | +$3.47M |
|
3
Sanofi
SNY
$121B
| $16.9M | 3.89% | 304,515 -80,000 | -21% | -$4.44M |
|
|
4
Nova
NVMI
$7.74B
| $16.7M | 3.85% | 90,697 +22,551 | +33% | +$4.16M |
|
5
AstraZeneca
AZN
$248B
| $12.9M | 2.96% | 175,060 -50,000 | -22% | -$3.68M |
|
|
6
BridgeBio Pharma
BBIO
$9.89B
| $12.7M | 2.92% | 366,608 -538,671 | -60% | -$18.6M |
|
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $10.1M | 2.32% | 157,931 +59,010 | +60% | +$3.77M |
|
8
Ultragenyx Pharmaceutical
RARE
$2.89B
| $9.68M | 2.23% | 267,385 +38,609 | +17% | +$1.4M |
|
9
Eli Lilly
LLY
$657B
| $9.65M | 2.22% | 11,690 -1,500 | -11% | -$1.24M |
|
10
Celldex Therapeutics
CLDX
$1.47B
| $9.22M | 2.12% | 507,829 +33,726 | +7% | +$612K |
|
11
Johnson & Johnson
JNJ
$427B
| $8.76M | 2.02% | 52,831 -17,000 | -24% | -$2.82M |
|
12
Novo Nordisk
NVO
$251B
| $8.2M | 1.89% | 118,080 +20,000 | +20% | +$1.39M |
|
13
Eledon Pharmaceuticals
ELDN
$155M
| $7.82M | 1.8% | 2,307,119 -244,500 | -10% | -$829K |
|
|
14
Mineralys Therapeutics
MLYS
$1.03B
| $7.39M | 1.7% | 465,526 +274,854 | +144% | +$4.36M |
|
15
Amazon
AMZN
$2.44T
| $6.96M | 1.6% | 36,607 -26,000 | -42% | -$4.95M |
|
16
AbbVie
ABBV
$372B
| $6.34M | 1.46% | 30,256 -4,000 | -12% | -$838K |
|
17
Pharvaris
PHVS
$1.39B
| $6.03M | 1.39% | 383,856 -4,327 | -1% | -$67.9K |
|
18
Ormat Technologies
ORA
$5.56B
| $5.94M | 1.37% | 84,000 +5,000 | +6% | +$354K |
|
19
Cytokinetics
CYTK
$4.23B
| $5.83M | 1.34% | 144,961 -8,060 | -5% | -$324K |
|
|
20
Meta Platforms (Facebook)
META
$1.86T
| $5.74M | 1.32% | 9,962 -11,039 | -53% | -$6.36M |
|
21
Novartis
NVS
$245B
| $5.57M | 1.28% | 50,000 | – | – |
|
22
Merck
MRK
$210B
| $5.35M | 1.23% | 59,600 | – | – |
|
23
Praxis Precision Medicines
PRAX
$958M
| $5.33M | 1.23% | 140,660 +49,077 | +54% | +$1.86M |
|
24
Nice
NICE
$8.73B
| $5.13M | 1.18% | 33,303 -9,197 | -22% | -$1.42M |
|
25
GSK
GSK
$79.9B
| $5.04M | 1.16% | 130,000 | – | – |
|